Sign In
Buy LTRN
$2.75
+0.140 (+5.36%)
At Close: Aug 04, 2026
Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors
08:00am, Monday, 28'th Jul 2025
DALLAS--(BUSINESS WIRE)--Dr. Lee Schalop Joins Lantern Pharma BOD.
Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial
07:56am, Wednesday, 23'rd Jul 2025
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage oncology company leveraging its proprietary RADR® artificial intelligence (AI) platform to systematically transform drug
Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy
08:20am, Monday, 21'st Jul 2025
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage oncology company leveraging its proprietary RADR® artificial intelligence (AI) platform to accelerate drug discovery, tod
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a pioneering artificial intelligence (AI) company transforming oncology drug discovery and development, today announced the launch of an in
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform, today announces rema
DALLAS--(BUSINESS WIRE)--ATRT data presented at SNO Pediatric 2025.
Lantern Pharma Inc. (LTRN) Q1 2025 Earnings Call Transcript
03:04pm, Thursday, 15'th May 2025
Lantern Pharma Inc. (NASDAQ:LTRN ) Q1 2025 Earnings Conference Call May 15, 2025 9:00 AM ET Company Participants Panna Sharma - President & CEO David Margrave - CFO Conference Call Participants Operat
Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates
08:45am, Thursday, 15'th May 2025
DALLAS--(BUSINESS WIRE)--Q1 2025 Lantern Pharma Earnings (LTRN).
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (Nasdaq: LTRN), an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary AI platform, RADR®, today
Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET
08:30am, Thursday, 08'th May 2025
DALLAS--(BUSINESS WIRE)--Q1 Earnings Call Save The Date.
Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC)
08:55am, Monday, 05'th May 2025
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (Nasdaq: LTRN), an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary AI platform, RADR®, today
Lantern Pharma Inc. (LTRN) Q4 2024 Earnings Call Transcript
08:35pm, Thursday, 27'th Mar 2025
Lantern Pharma Inc. (NASDAQ:LTRN ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 AM ET Company Participants Panna Sharma - President and CEO David Margrave - Chief Financial Officer Kishor Bhat
Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results
04:01pm, Thursday, 27'th Mar 2025
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platfor
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET
08:00am, Thursday, 20'th Mar 2025
DALLAS--(BUSINESS WIRE)--Q4 & Fiscal Year 2024 Earnings Call Save The Date.
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform, today announced that
